Clinical trials: Lymphoma, Malignant
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL
- Trial name
- NCT03379051
- Testing
- Venetoclax, Umbralisib, Ublituximab
- Where
- 3 sites in United States
- Volunteers
- 78 people
- Sponsor
- TG Therapeutics, Inc.
Lymphoma
A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects
TThe study is being conducted to evaluate the relative bioavailability, pharmacokinetics and safety of different tablet processes of SHR2554 in healthy adult subjects.
- Trial name
- NCT05049083
- Testing
- New Process SHR2554 tablet、Former Process SHR2554 tablet, Former Process SHR2554 tablet、New Process SHR2554 tablet
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Lymphoma
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
This single arm, multicenter study will evaluate the safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab in previously untreated participants with cluster of differentiation 20 positive (CD20+) DLBCL or FL.
- Trial name
- NCT01889069
- Testing
- Rituximab, Cyclophosphamide, Vincristine
- Where
- 39 sites in Italy
- Volunteers
- 159 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
This is a multi-cohort, open-label study in previously untreated participants with chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), excluding those with the 17p deletion, to evaluate a debulking strategy that…
- Trial name
- NCT03406156
- Testing
- Obinutuzumab, Bendamustine, Venetoclax
- Where
- 15 sites in United States
- Volunteers
- 120 people
- Sponsor
- AbbVie
Lymphoma
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of parsaclisib in the treatment of Japanese participants diagnosed with previously-treated B-cell lymphoma.
- Trial name
- NCT03314922
- Testing
- Parsaclisib
- Where
- 6 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Incyte Corporation
T Cell Lymphoma
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory T or B cell malignancies.
- Trial name
- NCT04502446
- Testing
- CTX130
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 49 people
- Sponsor
- CRISPR Therapeutics AG
Non-Hodgkin's Lymphoma
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199
This is an open-label multicenter, study to assess the pharmacokinetic interaction of ketoconazole with ABT-199 in up to 12 subjects with relapsed or refractory non-Hodgkin's lymphoma.
- Trial name
- NCT01969669
- Testing
- ABT-199, Ketoconazole
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- AbbVie
Renal Cell Carcinoma, Non-hodgkin's Lymphoma
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
The purpose of this study is to determine if MDX-1203 is safe for the treatment of renal cell carcinoma or non-hodgkin's lymphoma.
- Trial name
- NCT00944905
- Testing
- MDX-1203
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Mitral Valve Regurgitation
CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study
Clinical study to evaluate the safety and performance of the CardiAQ-Edwards™ Transcatheter Mitral Valve
- Trial name
- RELIEF (NCT02722551)
- Testing
- Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve
- Where
- 15 sites in Canada, Denmark and 5 more
- Sponsor
- Edwards Lifesciences
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03802695
- Testing
- OrcaGraft (Orca-Q)
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Orca Biosystems, Inc.
Lymphoma
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
This open-label, multicenter, global study is designed to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of intravenous atezolizumab (MPDL3280A) and obinutuzumab in participants with refractory or…
- Trial name
- NCT02220842
- Testing
- Atezolizumab, Obinutuzumab, Tazemetostat
- Where
- 15 sites in United States, France and 3 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
NHL, B-cell NHL
Safety Study of NHL With 90Y-hLL2 IgG
This will be an open label, multiple center, non-randomized, dose-escalation Phase I/II trial, designed to evaluate the safety and effectiveness of a repeated, outpatient regimen utilizing IMMU-hLL2 intact monoclonal antibody IgG…
- Conditions
- NHL, B-cell NHL, Non-Hodgkins Lymphoma
- Trial name
- NCT00421395
- Testing
- 90Y-hLL2
- Where
- 5 sites in France, Germany
- Volunteers
- 59 people
- Sponsor
- Gilead Sciences
Novel Coronavirus Pneumonia
Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19
This study was conducted in a randomized, double-blind, placebo-controlled, multicenter clinical trial design. Two groups were designed, the experimental group and the placebo control group.
- Trial name
- NCT05305456
- Testing
- Tanreqing capsule, Tanreqing capsule simulator
- Where
- 2 sites in China
- Volunteers
- 480 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
This study will evaluate the efficacy and safety of duvelisib in combination with bendamustine and rituximab (DBR) vs placebo in combination with bendamustine and rituximab (PBR) in subjects with previously-treated indolent…
- Conditions
- Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT02576275
- Testing
- Duvelisib, Rituximab, Bendamustine
- Where
- 7 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- SecuraBio
Hodgkins Lymphoma
Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
This is a Phase 1b, open-label, multi-center study comprising a lead-in phase and an expansion phase. The lead-in phase is a multiple-dose, randomized, parallel-arm, pharmacokinetic and pharmacodynamic study of avelumab as a…
- Trial name
- NCT02603419
- Testing
- Avelumab
- Where
- 13 sites in United States, Italy and 1 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Acute Lymphocytic Leukemia
A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia.
The purpose of this study is to learn about the safety of BESPONSA for pediatric patients. . BESPONSA is approved for treatment of relapsed or refractory CD22-positive acute lymphocytic leukemia for pediatric patients.
- Trial name
- NCT06476665
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Follicular Lymphoma (FL)
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).
- Trial name
- NCT07562022
- Testing
- SCTB35 injection, Rituximab, Lenalidomide
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Sinocelltech Ltd.
Lymphoma
Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas
A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients with Relapsed or Refractory Lymphomas
- Trial name
- NCT03119467
- Testing
- RP4010
- Where
- 11 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Rhizen Pharmaceuticals SA
Relapsed/Refractory Mantle Cell Lymphoma
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
The goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (KTE-X19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL) who have not previously received Bruton's…
- Trial name
- ZUMA-2 (NCT04880434)
- Testing
- Fludarabine, Cyclophosphamide, Brexucabtagene autoleucel
- Where
- 40 sites in United States, France and 4 more
- Volunteers
- 95 people
- Sponsor
- Kite, A Gilead Company
Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
The main aims of this 2-part study are: Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise…
- Conditions
- Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- CASSANDRA (NCT05908409)
- Testing
- IDP-121
- Where
- 11 sites in Spain
- Volunteers
- 37 people
- Sponsor
- IDP Discovery Pharma S.L.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.